Definium 制药
DFTX
32.10
-2.16
-6.30%
Definium 制药
US · DFTX
#2132 按市值排名
上市于 1970
32.10
-2.16
-6.30%
实时 - 追踪5344个代码 - 心跳于422秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量增加了2家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 87.51% -0.01pp
- 机构数量
- 414 +2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund57.29%
Hedge Fund21.23%
VC/PE Fund5.65%
Public Company1.65%
Individual/Insider1.49%
Insurance Company0.56%
Private Company0.42%
Family Office/Trust0.35%
Government Pension Fund0.30%
Other11.06%
主要股东 截至 2026-06-30
BlackRock
8.36% · 11.23M 股
Capital Research
6.20% · 8.33M 股
Avoro Capital Advisors LLC
5.35% · 7.19M 股
Driehaus Capital Management LLC
5.09% · 6.85M 股
Janus Henderson Group plc
4.18% · 5.62M 股
FMR
3.54% · 4.75M 股
T. Rowe Price Group, Inc.
3.46% · 4.65M 股
Geode Capital Management, LLC
2.71% · 3.64M 股
State Street Global Advisors
2.28% · 3.07M 股
Octagon Capital Advisors LP
2.20% · 2.95M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 36次买入 · 14次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Daniel Karlin | Chief Medical Officer | 0.43% |
| Robert Barrow | Chief Executive Officer | 0.33% |
| Matthew Wiley | Chief Commercial Officer | 0.27% |
| Brandi Roberts | Chief Financial Officer | 0.20% |
| Mark Sullivan | Chief Legal Officer | 0.19% |
| Schond Greenway | Chief Financial Officer | 0.02% |
| Roger Crystal | Independent Director | 0.01% |
| Suzanne Bruhn | Independent Director | 0.01% |
| Carol Vallone | Independent Chairperson | 0.01% |
| Andreas Krebs | Independent Vice Chairperson | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-24 | Mark Sullivan | Chief Legal Officer | Automatic Disposition | -14,051 | $36.57 |
| 2026-09-24 | Brandi Roberts | Chief Financial Officer | Automatic Disposition | -3,377 | $36.57 |
| 2026-09-24 | Matthew Wiley | Chief Commercial Officer | Automatic Disposition | -3,097 | $36.57 |
| 2026-09-24 | Robert Barrow | Chief Executive Officer | Automatic Disposition | -31,550 | $36.57 |
| 2026-09-24 | Daniel Karlin | Chief Medical Officer | Automatic Disposition | -10,853 | $36.57 |
| 2026-09-17 | Carol Vallone | Independent Chairperson | Derivative Exercise and Retained | +1,086 | $35.52 |
| 2026-09-17 | Andreas Krebs | Independent Vice Chairperson | Derivative Exercise and Retained | +1,629 | $35.52 |
| 2026-09-13 | Mark Sullivan | Chief Legal Officer | Other Acquisition | +125,000 | -- |
| 2026-09-13 | Brandi Roberts | Chief Financial Officer | Other Acquisition | +125,000 | -- |
| 2026-09-13 | Matthew Wiley | Chief Commercial Officer | Other Acquisition | +125,000 | -- |
| 2026-09-13 | Robert Barrow | Chief Executive Officer | Other Acquisition | +750,000 | -- |
| 2026-09-13 | Daniel Karlin | Chief Medical Officer | Other Acquisition | +200,000 | -- |
| 2026-09-02 | Robert Barrow | Chief Executive Officer | Automatic Disposition | -19,023 | $37.94 |
| 2026-09-01 | Robert Barrow | Chief Executive Officer | Other Acquisition | +40,000 | -- |
| 2026-08-11 | Mark Sullivan | Chief Legal Officer | Other Acquisition | +62,500 | -- |
| 2026-08-11 | Brandi Roberts | Chief Financial Officer | Other Acquisition | +62,500 | -- |
| 2026-08-11 | Matthew Wiley | Chief Commercial Officer | Other Acquisition | +62,500 | -- |
| 2026-08-11 | Robert Barrow | Chief Executive Officer | Other Acquisition | +375,000 | -- |
| 2026-08-11 | Daniel Karlin | Chief Medical Officer | Other Acquisition | +100,000 | -- |
| 2026-06-24 | Mark Sullivan | Chief Legal Officer | Automatic Disposition | -13,008 | $45.03 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:16 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Definium 制药 讨论区 0 条评论